CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
PACT4EYE focuses on developing a novel treatment for uveal melanoma using photoactivated chemotherapy. This method employs a light-activated prodrug to target tumors directly, minimizing side effects and potentially improving survival rates for patients with this rare eye cancer.
Uveal melanoma (UM) is a rare tumor of the eye; its current treatment leads to lower quality-of-life for the patients (sight loss), 50% of whom eventually die from metastases to the liver.
The PACT4EYE project aims at the first clinical development of a new technique called photoactivated chemotherapy (PACT) for the treatment of UM.
It makes use of a new, patented ruthenium-containing prodrug (Ru-MTI) that must be activated by green or red light to become toxic. PACT uses laser light irradiation…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Paris
Type: Research institute
Activity type: Research Organisations
SME: No
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Martignacco Ud
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
